{
    "id": "dbpedia_1753_2",
    "rank": 80,
    "data": {
        "url": "https://www.novonordisk-us.com/",
        "read_more_link": "",
        "language": "en",
        "title": "Welcome to Novo Nordisk in the U.S.",
        "top_image": "https://www.novonordisk-us.com/content/dam/nncorp/us/en_us/homepage/us-dfp-2018-photo-hires-KLTY-4.jpg",
        "meta_img": "https://www.novonordisk-us.com/content/dam/nncorp/us/en_us/homepage/us-dfp-2018-photo-hires-KLTY-4.jpg",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.",
        "meta_lang": "en",
        "meta_favicon": "/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico",
        "meta_site_name": "Novo Nordisk",
        "canonical_link": "https://www.novonordisk-us.com/",
        "text": "Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to USD 19.3 billion in the first six months of 2024\n\nOzempic® (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Association\n\nHere are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile."
    }
}